WeVote

Bill

Bill

HB 838

State Board of Pharmacy - Prescriber-Pharmacist Agreements

2026 Regular Session Introduced by Tiffany Alston and 17 co-sponsors

HB 838 requires written prescriber-pharmacist agreements in Maryland, formalizing professional collaboration standards and pharmacist clinical service roles.

Approved by the Governor - Chapter 53
0
WeVote Research Nonpartisan
Bill Summary · HB 838

Legislative bill overview

HB 838 would establish requirements for written agreements between prescribers and pharmacists in Maryland, likely governing collaboration on medication therapy management, prescription review, and clinical services. The bill appears to formalize the regulatory framework for pharmacist-prescriber relationships under the State Board of Pharmacy's oversight. This represents an attempt to standardize professional interactions in healthcare delivery.

Why is this important

Pharmacists increasingly provide clinical services beyond dispensing, including medication management and patient counseling, making clear professional boundaries essential. Formalizing these agreements can improve patient safety, reduce medication errors, and clarify liability and responsibility between healthcare providers. The bill addresses evolving roles in pharmacy practice that current regulations may not adequately address.

Potential points of contention

  • Scope of practice concerns: Prescribers may resist agreements that appear to grant pharmacists independent decision-making authority, viewing this as encroachment on prescribing privileges
  • Administrative burden: Small independent pharmacies and medical practices could face compliance costs and paperwork requirements that larger chains more easily absorb
  • Standardization vs. flexibility: Mandated agreement requirements may prove too rigid for diverse practice settings (rural clinics, hospitals, retail pharmacies) with different operational needs

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.